Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
PCVX Vaxcyte, Inc. daily Stock Chart
PCVX [NASD]
Vaxcyte, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.19 Insider Own2.20% Shs Outstand50.92M Perf Week27.58%
Market Cap2.41B Forward P/E- EPS next Y-2.52 Insider Trans0.00% Shs Float28.17M Perf Month-0.43%
Income-73.40M PEG- EPS next Q-0.44 Inst Own82.50% Short Float0.22% Perf Quarter42.37%
Sales- P/S- EPS this Y-70.50% Inst Trans- Short Ratio0.41 Perf Half Y-
Book/sh32.46 P/B1.55 EPS next Y59.90% ROA- Target Price49.50 Perf Year-
Cash/sh8.58 P/C5.88 EPS next 5Y-0.60% ROE- 52W Range17.80 - 55.04 Perf YTD93.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.30% Beta-
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low183.54% ATR4.59
Employees43 Current Ratio12.60 Sales Q/Q- Oper. Margin- RSI (14)65.96 Volatility11.42% 10.37%
OptionableNo Debt/Eq0.00 EPS Q/Q-488.80% Profit Margin- Rel Volume21.57 Prev Close49.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume152.70K Price50.47
Recom1.50 SMA2013.95% SMA5030.63% SMA20037.40% Volume3,294,148 Change2.12%
Jul-07-20Initiated Needham Buy $40
Jul-07-20Initiated Cantor Fitzgerald Overweight $55
Jul-07-20Initiated BofA Securities Buy $37
Sep-14-20 02:27PM  
We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
Simply Wall St.
Sep-09-20 05:28PM  
Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference
GlobeNewswire
Aug-14-20 03:01PM  
Dow Jones Edges Higher In New Bid For 28,000; Tesla, AMAT Stock Lead Nasdaq
Investor's Business Daily +8.71%
Aug-12-20 04:59PM  
CORRECTION Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update
GlobeNewswire +8.00%
04:10PM  
Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update
GlobeNewswire
Jun-16-20 04:05PM  
Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire +15.36%
Jun-12-20 11:24AM  
Vaccine maker Vaxcyte's shares soar 22% in trading debut
MarketWatch
06:18AM  
Vaccine maker Vaxcyte upsizes IPO and prices at top end of range
MarketWatch
01:06AM  
Vaxcyte Announces Pricing of Upsized Initial Public Offering
GlobeNewswire
Jun-03-20 08:30AM  
Vaxcyte Appoints Halley E. Gilbert to Board of Directors
GlobeNewswire
May-21-20 08:30AM  
SutroVax Announces Name Change to Vaxcyte
GlobeNewswire
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
open in yahoo | open in reuters | open in google